...A. headquartered in Minneapolis, 3,100 people and last year, $1.1 billion. B. 10% of the revenues related to instruments, seven plus two related to services and royalties, 81% related to consumables and out of that 81% the 10% of that are consumables directly related to the instruments. C. Now, the company reports in two segments, Protein Sciences segment, we call it PSS as well as the Diagnostics and Genomics segment called DGS. D. In PSS, we have three business units that are fully focused on core products, such as proteins, antibodies and immunoassays and there are also two growth verticals. E. So how the revenues break out amongst those growth verticals is on this slide and you see in the top left here, 74% for the PSS segment, the [lion's] share and 26% of the revenues are related to diagnostics and genomics. F. The core, the 44%, the core that is in protein sciences, 44% of Bio-Techne's revenue. G. But you see that cell and gene therapy is growing fast, so now 7% and the protein analytical...
